

VIEKIRA PAK (COPACKAGED) - (250MG;12.5MG, 75MG, 50MG ; Tablet)

Generic Name	DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR	Innovator	Abbvie
Dosage	250MG;12.5MG, 75MG, 50MG ; Tablet	Branded US Sales	Less Than \$1000 mn
Probable FTF	None	Known Para IV Filers	None
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	VIEKIRA PAK is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV): • genotype 1b without cirrhosis or with compensated cirrhosis • genotype 1a without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.